Pulmatrix and Eos Merge into Eos SENOLYTIX with $19M Financing for PTC-2105
Pulmatrix will acquire Eos SENOLYTIX under a definitive merger, creating Eos SENOLYTIX, Inc. with expected Nasdaq listing as EOSX and concurrent $19 million private financings led by Rapha Capital Management. Net proceeds will advance its MitoXcel™ platform, including PTC-2105 clinical candidate targeting sarcopenia and sarcopenic obesity.
1. Merger Overview
Pulmatrix and Eos SENOLYTIX have entered a definitive merger agreement under which Pulmatrix will acquire Eos. The combined entity, named Eos SENOLYTIX, Inc., is expected to trade on Nasdaq under ticker EOSX upon closing in mid-2026, subject to stockholder and regulatory approvals.
2. Financing Details
Concurrent with the merger, the companies secured $19 million in private financings managed by Rapha Capital Management, including a $1 million investment from RCM Eos PIPE HOLDINGS LLC and a bridge component from RCM Eos Holdings, LLC. Net proceeds are earmarked for clinical advancement of the MitoXcel™ platform.
3. Lead Candidate PTC-2105
PTC-2105, the combined company’s lead clinical candidate, is a mitochondrial-targeted geropeptide designed to treat sarcopenia and sarcopenic obesity. Preclinical data show significant fat mass reduction, lean mass gains and improved physical function without reduced food intake or rebound weight gain.
4. Ownership Structure and Timeline
Post-merger, pre-merger Pulmatrix shareholders will hold approximately 6% of the combined company while Eos stockholders and financing participants will own about 94%. The transaction is expected to close in mid-2026 following customary closing conditions, including approval of a Form S-4 registration statement.